Representative CT imaging in patients with a durable clinical response.
esophageal cancer, Multiple liver metastases, cancer, Esophageal cancer, pleural tumor
METASTASIS, OESOPHAGEAL CANCER, CANCER, PLEURAL METASTASIS, LYMPH NODE METASTASIS, ESOPHAGEAL CANCER, DISEASE PROGRESSION
(a) Esophageal cancer patient B-09. Pleural metastasis (yellow arrow) was observed on CT and FDG-PET at baseline. The pleural tumor was decreased in size by the KW-0761 treatment, which was also confirmed by a reduction in standardized uptake value-max (SUV-max) on FDG-PET. Although pleural metastasis shrank, abdominal lymph node metastasis (orange arrow) developed after 23 infusions, which was evaluated as a new lesion, leading to the discontinuation of treatment. (b) Esophageal cancer patient B-39. Multiple liver metastases (yellow arrow) were observed on CT at baseline. Disease progression and a new lesion in the liver (red arrow) were confirmed after the first 8 infusions; however, all lesions subsequently decreased in size. The objective feasible response was sustained until 36 weeks after the first treatment when abdominal lymph node metastasis developed (orange arrow).Patient B-39 was a 59-year-old female with chemotherapy-resistant relapsed metastasis in the liver from esophageal cancer (Although 2 patients with esophageal cancer showed a durable clinical response, there was no significant prognostic difference between patients with esophageal cancer and those with other cancer types (